Infectious Disease Alert – June 1, 2008
June 1, 2008
View Issues
-
Molecular Identification of Head Lice from Peruvian Mummy
Mummies are fascinating. they represent a special snapshot of our human past when contemporaries respected our human forms enough to try to preserve them indefinitely. -
Laboratory-acquired Infections Beyond Bioterrorism
Threats to laboratory workers come in many varieties, ranging from earthquakes to fires. But one threat that has acquired enhanced visibility in this age of bioterrorism is the threat of a laboratory-acquired infection. -
Relationship between CD4+ Count and Non-AIDS Diseases in HIV Patients
Exactly 1397 antiretroviral (ARV) naïve patients initiating ARVs, as part of a CPCRA-sponsored clinical trial (FIRST trial), were followed for a median of five years. -
MRSA Screening — Making Sense of Surveillance
The utility of surveillance screening for MRSA on hospital admission remains controversial. Three recently published clinical trials attempt to assess the role of MRSA surveillance. -
Decreased Pneumococcal Meningitis after PCV7 Implementation: Another Vaccine Success Story
Pneumococcal meningitis remains a deadly disease, with a case fatality rate among adults that is still above 20%, with also permanent neurological sequelae in a substantial minority of survivors. -
Infection Control Measures in a Combat Zone
All patients admitted to the ICU at the Air Force Theater Hospital (Balad, Iraq) were followed prospectively for the development of VAP. There were 475 patients admitted to the ICU from May 2006 through August 2006. -
Updates by Carol A. Kemper, MD, FACP
In the health care setting, transmission of varicella zoster virus (VZV) from dermatomal herpes zoster lesions is generally felt to be insignificant, as long as the lesions are kept covered. -
Pharmacology Watch: New Study on Thiazolidinediones May Show Benefits
In this Issue: Pioglitazone and heart disease; ARBs manufacturers spend millions to show the non-inferiority of their products compared to less expensive, generic ACE inhibitors; some athletes turn to growth hormone because it is difficult to detect; FDA Actions -
Clinical Briefs in Primary Care supplement